Clinical Trials Directory

Trials / Completed

CompletedNCT03356548

Transferrin Saturation and Asthenia in Hemochromatosis

Study of the Association Between Transferrin Saturation and Asthenia in Hemochromatosis

Status
Completed
Phase
Study type
Observational
Enrollment
260 (actual)
Sponsor
Rennes University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Observational study.

Detailed description

The linked HFE genetic hemochromatosis (C282Y mutation in the homozygous state) is the most common form of genetic iron overload. Its treatment is based on bloodletting, and takes place in 2 phases, according to the recommendations of the High Authority of Health (HAS). The first phase, called induction, aims to achieve ferritinemia \<50 by performing weekly bleeds. The second phase, called maintenance, aims to maintain this ferritinemia \<50 by performing bleeding every 1 to 6 months depending on the case. The treatment is therefore according to the current recommendations only adapted according to ferritinemia, and not according to the effectiveness on the functional symptoms. However, some patients report persistent asthenia during maintenance treatment, despite ferritin levels \<50. This could reflect an incomplete control of their disease, and leads us to raise two points: * It is known that in some subjects, the Transferrin Saturation Coefficient remains high, despite ferritinemia \<50; it is also known that this elevation of the Transferrin Saturation Coefficient may be accompanied by a rise in circulating free iron, which is toxic for the organism1. * The asthenia observed in some patients in the maintenance phase could be linked to a high rate of Transferrin Saturation Coefficient. Our objective is to evaluate, in patients homozygous C282Y in maintenance phase, the association between quality of life and Transferrin Saturation Coefficient .

Conditions

Timeline

Start date
2017-04-10
Primary completion
2019-04-09
Completion
2019-04-09
First posted
2017-11-29
Last updated
2019-07-31

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03356548. Inclusion in this directory is not an endorsement.